[Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

James Jones, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a series of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred daily from September 2, 2025 through September 30, 2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported purchase on September 30, 2025, the filing shows 44,192 shares beneficially owned by the reporting person. All transactions are reported as acquisitions and are marked as direct ownership.

Positive

• Director increased direct ownership to 44,192 shares
• Purchases executed under a Rule 10b5-1 plan adopted on Nov 14, 2024, indicating pre-planned activity

Negative

• None.

Insights

Corporate Governance Expert

Director executed scheduled purchases via a 10b5-1 plan, steadily increasing holdings.

The filing shows a pre-established Rule 10b5-1 trading plan dated Nov 14, 2024, which legally permits automatic purchases even during blackout windows when properly adopted.

The director acquired shares across September 2–30, 2025, taking direct ownership to 44,192 shares; prices reported range from $3.05 to $3.60. This pattern reflects systematic purchases rather than ad hoc trades.

Equity Markets Specialist

Small, regular purchases reported; individual transactions are modest in size and price.

The transaction prices listed indicate purchases in the low single-digit dollar range ($3.05–$3.60), executed on multiple consecutive trading days, and all are recorded as acquisitions.

There is no disclosure in this Form 4 of option exercises, sales, or derivative activity; only non-derivative common stock purchases are shown, and ownership is direct.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jones James

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		L	V	12(1)	A	$3.54	43,950	D
Common Stock	09/03/2025		L	V	12(1)	A	$3.58	43,962	D
Common Stock	09/04/2025		L	V	12(1)	A	$3.6	43,974	D
Common Stock	09/05/2025		L	V	12(1)	A	$3.6	43,986	D
Common Stock	09/08/2025		L	V	12(1)	A	$3.41	43,998	D
Common Stock	09/09/2025		L	V	12(1)	A	$3.43	44,010	D
Common Stock	09/10/2025		L	V	12(1)	A	$3.39	44,022	D
Common Stock	09/11/2025		L	V	12(1)	A	$3.41	44,034	D
Common Stock	09/12/2025		L	V	12(1)	A	$3.54	44,046	D
Common Stock	09/15/2025		L	V	12(1)	A	$3.5	44,058	D
Common Stock	09/16/2025		L	V	12(1)	A	$3.5	44,070	D
Common Stock	09/17/2025		L	V	12(1)	A	$3.38	44,082	D
Common Stock	09/18/2025		L	V	12(1)	A	$3.31	44,094	D
Common Stock	09/19/2025		L	V	12(1)	A	$3.34	44,106	D
Common Stock	09/22/2025		L	V	12(1)	A	$3.29	44,118	D
Common Stock	09/23/2025		L	V	12(1)	A	$3.21	44,130	D
Common Stock	09/24/2025		L	V	12(1)	A	$3.1	44,142	D
Common Stock	09/25/2025		L	V	12(1)	A	$3.1	44,154	D
Common Stock	09/26/2025		L	V	12(1)	A	$3.05	44,166	D
Common Stock	09/29/2025		L	V	13(1)	A	$3.14	44,179	D
Common Stock	09/30/2025		L	V	13(1)	A	$3.12	44,192	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	James Jones by /s/ John Hamm as attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did James Jones report in the CPIX Form 4?

The filing reports a series of direct purchases of CPIX common stock from Sept 2–30, 2025, executed under a 10b5-1 trading plan, resulting in 44,192 shares beneficially owned.

What prices were paid for Cumberland Pharmaceuticals (CPIX) shares?

Reported per-share prices range from $3.05 to $3.60 across the transactions disclosed in September 2025.

Were any derivative securities reported in the Form 4?

No. Table II for derivative securities shows no entries; only non-derivative common stock purchases are reported.

Was the Form 4 filed jointly or by one reporting person?

The form is filed by one reporting person and the reporting person is identified as a director.

When was the 10b5-1 trading plan adopted?

The filing states the trading plan was adopted on November 14, 2024.